Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study

Genitourinary Cancer

Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy

BJU Int

Subiela JD, de la Parra I, Taborda J, Medina AA, Pichler R, Krajewski W, Ojeda CM, Mardomingo AF, Durán PDO, Pérez EL, González-Padilla DA, Aumatell J, Mori K, Scilipoti P, Longoni M, de Angelis M, Caño-Velasco J, Puentedura AL, Pujol LP, Contieri R, Gallioli A, Tukiendorf A, D'Andrea D, Teoh JY, Afferi L, Del Giudice F, Marcq G, Albisinni S, Soria F, Mertens LS, Laukhtina E, Tully K, Mari A, Guerrero-Ramos F, Alvarez-Maestro M, Martín CC, Melendres FA, Buisan O, López-González JA, Dominguez-Escrig JL, Aranda J, Elena JLR, Basile G, Santos VGD, Moschini M, Pradere B, Acosta EA, Palacio FL, Puig AC, Gajate P, Saiz A, Gontero P, Revilla FJB, From Young Academic Urologist: Urothelial Carcinoma Working Group

doi: 10.1111/bju.16913

Genitourinary Cancer

Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer

BJU Int

Scilipoti P, Zaurito P, Longoni M, Tremolada G, Occhi A, Dutto D, Katzendorn O, Krajewski W, Laukhtina E, Elena JLR, Aranda J, Contieri R, Hurle R, Subiela JD, Lucena PE, Fernández A, Marcq G, Szostek A, Pichler R, Álvarez-Maestro M, Bazán AA, Klatte T, du Biest AM, Ferrando V, Buisan O, López AV, Soria F, Pradere B, D Andrea D, Shariat SF, Colecchia M, Montorsi F, Briganti A, Gontero P, Xylinas E, Moschini M, European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators

doi: 10.1111/bju.70182

COMMENTED

Genitourinary Cancer

Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

Eur Urol

Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M

doi: 10.1016/j.eururo.2025.12.022

COMMENTED

Genitourinary Cancer

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

J Clin Oncol

Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group

doi: 10.1200/JCO-25-01324

Genitourinary Cancer

External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management

BJU Int

Rubio-Briones J, Guerrero Ramos F, Mercadé Sánchez A, Bezana Abadía I, Rodríguez RM, Alcaraz A, Miqueleiz Legaz M, Lozano F, Arrabal Martín M, Luis Cardo A, Gonzalo Rodríguez V, Caño Velasco J, Serrano Liesa M, Ferreiro Pareja C, Espílez Ortiz R, de González-Valcárcel de Torres I, Sánchez Zalabardo D, Esquinas C, Mengual L, Borque-Fernando A, Esteban Escaño LM, Palou Redorta J, Witjes F, Martínez Piñeiro L

doi: 10.1111/bju.70010

Genitourinary Cancer

Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin

J Urol

Bahlburg H, Maas M, Contreras-Sanz A, Othman D, St-Laurent MP, Nikkola J, Chai S, Phillips KG, Hamlington B, Lentz PS, Lumbres NP, Bicocca VT, Jalanko T, Levin TG, Lange D, Black PC

doi: 10.1097/JU.0000000000005130

Genitourinary Cancer

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer

BJU Int

Abou Chakra M, McElree IM, Mott SL, O'Donnell MA

doi: 10.1111/bju.70149

Endocrine and Neuroendocrine Tumors (NET)

Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

Int J Cancer

Matsubara Y, Masuishi T, Hosoda W, Hirano H, Mishima S, Takahashi H, Otsuka T, Kawasaki K, Kawakami T, Yanagihara K, Shimura T, Komoda M, Murayama K, Minashi K, Yamamoto Y, Shinohara Y, Nishina S, Musha N, Kato K, Kawakami K, Shinozaki K, Tsuchihashi K, Ando T, Kito Y, Makiyama A, Mitani S, Hino K, Izawa N, Oze I, Muro K

doi: 10.1002/ijc.70053

Genitourinary Cancer

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group

Eur Urol

Gupta S, Li R, Hensley PJ, Daneshmand S, Faltas BM, Grivas P, Lobo N, Mir MC, Meeks JJ, Mouw KW, Moschini M, Necchi A, Oualla K, Pohar KS, Rosenberg JE, Schmidt B, Siefker-Radtke AO, Steinberg GD, Stenzl A, Buckley RJ, Kamat AM

doi: 10.1016/j.eururo.2026.01.029

Related content

Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy

Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer

Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer

External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management

Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer

Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group